vimarsana.com

Latest Breaking News On - Clinical trial access - Page 1 : vimarsana.com

Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC

Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.

Expert perspectivesEmerging therapiesLow grade serous ovarian cancerOvarian cancerRamp 201Novel therapyCombination therapyRecist responseEfficacy dataEfficacy outcomesRamp 301Multidisciplinary careHealthcare teamClinical trialsClinical trial accessAccess to clinical trials

Xtalks Announces its Life Science Webinar Calendar for May 2023

Toronto, ON (PRWEB) May 05, 2023 Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical

Honeycomb worldwide incDigital endpoint development for alzheimer diseaseDigital health technologies in decentralized clinical trialsCancer researchResearch consulting organizationCommunity settingDevice developmentPromise of liquid biopsy technologyClinical researchHow to improve cell line developmentDrug developmentReal time decision makingClinical trialsDigital health technologiesDecentralized clinical trialsPrecision medicine

Xtalks Announces its Life Science Webinar Calendar for May 2022

Toronto, ON (PRWEB) May 02, 2022 Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical

United statesResearch landscapeResearch sitesSafety solutions in decentralized clinical trialsHoneycomb worldwide incPerfect matchClinical trialsVirtual populations help accelerate accessNew drugsConducting early phase clinical trialsWay integrationsClinical trial managementClinical trial sitesDeliver better clinical dataEvolving research landscapeChallenges faced

vimarsana © 2020. All Rights Reserved.